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Personalised Medicine has become one of the best drivers of research and new product 
development in the pharmaceutical industry. It aims to develop more safe and efficient therapies 
with the application of pharmacogenomics. The overall purpose of this study was to compare 
the regulatory environments of the USA and EU and how they influence new product 
development in personalised medicine. The objective of the study was to analyse the regulatory 
requirements at different stages of the drug development process. The study was positioned as 
exploratory research and data was gathered using desk research approach. 
Three streams of literature were reviewed to gain theoretical insight in the topic: Innovation and 
New Product Development, and New Drug Development. It was found that there are vast 
differences in the processes and regulations the regulatory bodies of the USA and EU have set 
for pharmaceuticals and medical devices which do influence the speed in which new drugs and 
diagnostics devices are commercialised. The study revealed that the US market is more 
advantageous for commercialising new personalised medicines in comparison to the European 
market in terms of the speed of the commercialisation process. Another key finding was that the 
regulatory regimes in the two markets make Europe a more favourable market area for 
diagnostics companies operating in the field of personalised medicine in terms of speed of the 
commercialisation process and importance mandated by the regulatory body of combining 
therapeutics and diagnostics. 
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1.  INTRODUCTION 
 
1.1. Background 
 
Interest in biotechnology in the development of drugs or even as a substitute method to 
chemical components has gained significance in the last two decades or so (Simon & 
Kotler, 2003, 6; PM Coalition Report, 2009). 
 
Generally, the biotechnology industry is a growing industry. For instance despite of the 
financial crisis that hit the global economy in 2008/2009, the biotech industries have 
been experiencing growth. According Ernst and Young‟s Global Biotechnology report 
(2009, 16), the developments in the industry have been influenced, in large part, by” 
four sweeping paradigm-shifting trends of generic drugs, expansion of personalised 
medicine, health care reforms in the USA and the continued globalisation of the 
industry”. 
 
Interest in personalised medicine took off after the human genome project and since 
then, both the pharmaceutical and biotechnology industries have shown significant 
interest and progress in its development and application. It is arguably one of the best 
drivers of research and new product development in the pharmaceutical industry.  The 
concept refers to the use of an individual‟s molecular information when trying to match 
right patients with right drugs in terms of efficacy and safety. 
 
Being an evolving area of science and practice, personalised medicine drugs (PMDs) 
have faced both acceptance and criticism. On one side of the aisle, supporters of PMDs 
see a future where they will make health delivery more medically and cost efficient 
(Ginsburg & McCarthy, 2001; PMC report, 2009). On the other side, critics see PMDs 
as crossing the ethical boundaries of science and medicine (Dion-Labrie et. al, 2010). 
 
Literature abound on drug development process is based mainly on traditional chemical-
based drug development, and even in biotechnology generally (Gupta et al, 2007; 
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Styhre, 2006; Thomas, 1994). However, due to the special nature of PMDs and its rising 
significance in the pharmaceutical industry, a new academic interest is evolving that 
focuses on product development in the field of PMDs (Bock et al, 2000; Ginsburg & 
McCarthy, 2001; Hopkins et al, 2007). Would the process be influenced by the same 
scientific, policy and market forces that shape drug development in other areas of the 
pharmaceutical industry? 
 
In the light of the above question, and given my personal interest and internship in a 
Biotech Service company with focus on the PMD industry,  this study  seeks to explore 
the trends in the development of selected drugs in the PM field and their launch in both 
the US and European markets. Though there is growing evidence of advancements in 
emerging markets such as India and Brazil, evidence shows that the majority of the 
biotechnology companies, in terms of size, market capitalisation and activity, are still 
located in Europe and USA. 
 
The study will employ conceptual wisdom from theories of Innovation and New 
Product Development and International Business to analyse the global trends in the 
industry specifically with regards to the regulatory environments for PMD New Product 
Development. 
 
It is expected that the results would contribute to our understanding of the external 
regulatory environment influencing industry developments generally and PMDs 
specifically. 
 
 
1.2. Research Questions 
 
The overall purpose of the study is to compare the regulatory environments of the USA 
and EU and how they influence new product development in personalised medicine. 
Specifically the following objective has been set for the study: 
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To analyse the regulatory requirements at different stages of the drug development 
process. 
 
The above objective would be met with the following questions: 
1. What is the duration of the review process for granting Marketing Approvals in 
the US and in the EU? 
2. What is the time lapse between Marketing Approval and Launch of a new 
pharmaceutical in the US and in the EU? 
3.  What is the time lapse between the Launch of a new drug and the Launch of a 
biomarker test developed to assist with medical decisions related to the drug in 
the two markets? 
 
The research questions assume differences in the regulatory regimes of the USA and EU 
and that these differences might be significant in the new drug development process. 
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2.   LITERATURE REVIEW 
 
The study takes theoretical wisdom from three streams of literature:  Innovation and 
New Product Development, and New Drug Development. This chapter reviews existing 
literature in the three areas and draws implications for personalised medicine. 
 
 
2.1. Innovation and New Product Development 
 
Innovation has been researched by many academics through the years, hence there are 
numerous descriptions varying from exceedingly wide definitions to narrower ones 
depending on the interests of the authors. The meaning of the term innovation has 
evolved in the past 40 years from being considered merely as an idea or a process 
causing change to the widely accepted definition of a new concept needing to be 
successfully developed and commercialised in order to become an innovation.  
 
In its widest sense, innovation can be anything that is new to a business (Abernathy & 
Utterback, 1978). However, no matter how innovation has been described, the 
perception of newness to the parties involved in the process has always been part of it 
(Cumming, 1998). For instance, Van de Ven (1986, 591) adopted this approach stating 
that “ An Innovation is a new idea, which may be a recombination of old ideas, a 
scheme that challenges the present order, a formula, or a unique approach which is 
perceived as new by the individuals involved”. 
 
2.1.1. Types of Innovation 
 
In 1943, Schumpeter used the concept of radical innovation triggering the process of 
transformation in his economic theory which describes the impact innovations have on 
industries and economies. He divides innovation into groups depending on the type of 
innovation in question: introduction of a new commodity or production method, 
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opening a new market, changing the source of supply and reorganisation of an industry 
(Schumpeter, 1964, 59). The first two, introduction of a new product/production method 
and opening a new market, are considered technological innovations due to their 
economic output. 
 
To elaborate Schumpeter‟s categorisation of different types of innovation, Cumming 
(1998) and Hine & Kapeleris (2006, 5) identify four types of innovation: product 
innovation, process innovation, market innovation and technology innovation. To 
distinguish the different types of innovation even further, Trott (2005, 17) has written 
about organisational innovation, management innovation, production innovation and 
service innovation. 
 
According to Hine & Kapeleris (2006, 5), product innovation can be either major or 
incremental in nature. A product considered as a major product innovation is a 
commercialised invention which has been developed from entirely new ideas. However, 
this description has its limitations. For instance, even though one would be the first to 
create a new technology product, it is possible that the idea of the same or very similar 
invention has been in the minds of many, yet has not reached the development stage due 
to lack of technical aspects required (Cumming, 1998). Incremental product innovation 
differs from major product innovation in the idea generation phase. An incremental 
product innovation does not need to be developed from a radical idea but from a 
creative input added to enhance an existing product. As an example, developing a 
product with substantial improvements compared to an existing product either 
technically or economically. 
 
High level of competition in all markets forces companies to constantly think of ways to 
improve their performance. Already in 1974, Robertson wrote about innovation, 
describing it as “a series of technical, industrial and commercial steps”; process 
innovation. Process innovation‟s purpose is to create new methods for the production 
stage of new product development, aimed at enhancing the quality of the product and/or 
enable the product to be made with a lower cost and/or in a less time consuming 
manner. However, the process ought to be executed in such a way that improving one 
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variable would not result in drawbacks on others. For instance, cutting costs should not 
consequent in jeopardising the quality of the product (Cumming, 1998).  
 
Trott‟s analysis (2005, 17) distinguishes process and production innovation with the 
notion of process innovation being related to manufacturing processes, in comparison to 
production innovation; meaning new systems related to manufacturing, such as the just-
in-time (JIT) system.  
 
Another type of innovation, besides product; process; and production innovation, is 
market innovation. Companies use market innovation with the aim of finding new 
potential markets, and new ways of serving their target markets more efficiently. The 
process of market innovation begins from identifying potential markets which can be 
done through careful market segmentation. The segmentation can be conducted by 
choosing an objective variable such as a particular geographic area or a subjective 
variable such as data describing consumer and buying behavior (Johne, 1999). For 
example, consumers make buying decisions based on social, cultural, personal and 
psychological factors depending on the type of product needed. The four different types 
of buying behaviour: complex buying behaviour, dissonance-reducing buying 
behaviour, habitual buying behaviour and variety-seeking buying behaviour, can be 
used to segment consumers in groups in order to turn potential customers into actual 
market opportunities (Kotler et al, 2005, 276-278). 
 
Organisational- and management innovation deal with in-house procedures in 
businesses. Organisational innovation includes various systems and procedures taken 
upon in organisations in order to improve its activities, whereas management innovation 
consists of managerial systems such as total quality management (Trott, 2005, 17). 
Service innovation Trott describes as the new field in innovation enabled by the 
internet, for example financial services that are internet based belong to this category. 
 
A slightly differing approach for categorising innovation types was proposed by 
Damanpour in the early 1990s. He classifies innovation as either technological or non-
technological, also in consistence with the Schumpeterian approach, but the main 
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determinant of further sub-grouping is whether the innovation is considered 
technological or not. This is opposed to all different types of innovation mentioned 
above not segmented according to the features of the innovation but a more general 
typing. Therefore, technological innovation is further segmented to subgroups including 
products, services and processes, whereas non-technological innovation includes 
organisational processes and administration systems (Damanpour, 1991, 556).  
 
In literature on technological innovation, the term itself has also been used by many 
authors to describe the process a new technological product goes through starting from 
the idea generation, moving through the development of the product with the help of 
sciences into a finalised item; new product development (Styhre 2006; Cantisani, 2005). 
Besides, Styhre (2006) suggests that there is a relationship between scientific thinking 
and managerial objectives in science-based innovation in the pharmaceutical industry 
and that “innovation is very much the identification of the best possible fit between the 
favored problem definition and its suggested solution”. His view echoes to a large 
extent the study published by the Organisation for Economic Cooperation and 
Development (OECD) on innovation, which describes innovation as a process starting 
from identifying a new market opportunity for a technology-based invention which will 
be developed, produced and marketed with the aim of commercial success (OECD, 
1991). 
 
2.1.2. Innovation Models and Adoption 
 
In literature examining innovation, several models describing how innovation takes 
place have been introduced. The technology push model is a linear model which 
describes new product development as a sequential pattern beginning from inventing a 
new product, manufacturing followed by marketing activities, and consequently the 
product finding its way to the users. The technology push model was very popular after 
the Second World War, but in the late 1970s the importance of the needs of the market 
were emphasised and the market pull model was created. The market pull model is also 
linear yet the sequences happen in different order, starting from marketing (the needs of 
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the market investigated through communication with users of a particular product), after 
which the R&D activities and manufacturing take place, resulting the product ending up 
to the users. In addition to the technology push and market pull models, the 
simultaneous coupling model identifies manufacturing, marketing and R&D as the three 
functions that support the birth of innovation simultaneously, but on the contrary to the 
linear models, does not state the exact starting point (Trott, 2005,22-24, Schumpeter, 
1964, 58-62). 
 
The interactive model of innovation combines both of the linear models; technology 
push and market pull, but states that albeit the process would be sequential, it may not 
be continuous. The interaction comes from a flow of feedback originating from 
communication paths that provide information on the needs of society and marketplace, 
and also information on the latest scientific and technological advances in society 
(Trott, 2005, 24-25).  
 
The technology push model is descriptive of the traditional drug development process, 
considering the sequential path of phases starting from R&D, moving on to 
manufacturing and commercialisation of the new product. In addition, traditional drug 
development process aims to develop products for a large population to treat a certain 
disease or medical condition. It can be speculated that the new product development for 
personalised medicine drugs (PMDs) leans more towards the market pull model, seeing 
that the PMDs can be developed according to genotype and/or other individual 
characteristics to fit the needs of individual patients (Jain, 2009, 1). 
 
The diffusion of innovation theory by Rogers (1962, 2003) seeks to explain how 
innovations are adopted by individuals. He defines diffusion as "the process by which 
an innovation is communicated through certain channels over time among the members 
of a social system” (Rogers, 1963, 2003; 5). In his theory the importance of 
understanding the needs of different types of consumers transfers into subgroups of 
“adopters”: innovators, early adopters, early majority, late majority and laggards, with 
varying timescale of diffusion respectively.  The concept of re-invention is also central 
to the theory, describing how the occurring change does not necessarily happen in the 
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individuals using a particular innovation but in the innovation itself. This can be seen as 
an ongoing process of users improving the product to suit their needs best (Rogers, 
1963, 2003; 180, 281).  
 
In my study I adopted the definitions of OECD (1991), Rogers (1962, 2003), and Styhre 
(2006) that innovation is a process of successfully developing and commercialising a 
technology-based invention, adopted by different types of users in a varying order. In 
the pharmaceutical industry, new product development is fundamentally finding 
biomedical solutions to biomedical problems (Styhre, 2006).  
 
 
2.2. New Product Development Models 
 
The concept of new product development describes the stages it takes for an idea to be 
turned into a tangible product and commercialised in a chosen market. The stages 
involve generating a new idea, developing a concept based on the idea, manufacturing 
the product and creating a business strategy around it (Yelkur & Herbig, 1996). In order 
to explain the phenomenon of new product development using different methods, 
several models have been created. These models illustrate how there can be various 
routes on the way to the final destination of introducing a new product to the market. 
According to Saren (1984), there are seven distinct categories that comprise various 
models of new product development: departmental-stage models; activity-stage models 
and concurrent engineering; cross-functional models; decision-stage models; response 
models; network models; and conversion-process models. 
 
The Departmental Stage Model describes the path of developing a new product as 
various separate processes taking place in a highly compartmentalised environment. The 
first stage of the process would be the responsibility of a company‟s R&D department, 
the second stage, development of the product, the responsibility of the manufacturing 
department and commercialising the product would be handled by the marketing 
department. Yet, Trott (2005, 400-401) thinks separating the stages of the development 
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process into responsibilities of different departments, according to the activities required 
to complete a stage, within a company can have negative outcomes. For instance, if the 
communication channels between each of the departments do not work, the whole 
development process can slow down or the quality of the product may be compromised. 
Figure 1 describes how a Departmental Stage Model would look like if used in drug 
development environment. 
 
Figure 1 Departmental Stage Model 
 
Source:  Based on Trott, 2005, 400 
 
The Departmental Stage Model would describe new product development in the 
pharmaceutical industry happening within three different stages. The R&D department 
would be responsible for discovering a new drug, after which the drug would be 
developed in a laboratory environment, after which the marketing department would 
take care of commercialising the product. 
 
It can be noted that such a linear model may not necessarily result in commercial 
success, unless there is high level of communication between the departments; 
marketing department informing the R&D department of the current needs of the market 
and vice versa. However, this model does not guarantee high level of communication 
but relies on the expertise of each individual department. 
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Activity Stage Model is another model used to describe the stages occurring in new 
product development process.  The model sees new product development as separate 
activities taking place along the way of developing a product. The first stage of the 
process is idea generation, followed by idea screening. Idea screening is used in order to 
separate viable ideas that could be developed and hopefully generate revenue for a 
company, from ideas that may not work in real life. Only a fraction of the total number 
of ideas created, survive the screening process, which are then developed into concepts 
and further tested.  
 
Once the ideas that qualify after the screening process have been chosen, business 
analysis can be conducted. This is done before the initial product development begins in 
order to minimise risks in terms of the likeliness of the product to succeed in the market. 
Once the product has been developed, it will be test marketed which means a chosen 
consumer group, sample, will use the product. Based on the results of test marketing, 
the company developing the product still has a chance to change some of the features in 
the product in attempt to please the consumers more, based on the recommendations 
given by the sample group. The final stages of the Activity Stage Model are 
commercialising the product and monitoring and evaluating its success. By 
commercialisation, making the product available in the mass market is meant. Figure 2 
demonstrates the activities occurring in the Activity Stage Model. 
 
Figure 2 Activity Stage Model 
 
 
 
Source: Based on Trott 2005, 398 
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The Activity Stage Model suggests that new product development happens in stages 
that follow each other in a consecutive order. The Activity Stage Model describes rather 
well the traditional process of new drug development, focusing on activities taking 
place in a sequential order. The concept of Activity Stage Model stresses the importance 
of communication between activities, in comparison to the less communication focused 
Departmental Stage Model. According to Trott (2005, 400-402), continuous 
communication across activities taking place in the Activity Stage Model improves the 
efficacy of the process.  
 
However, activity-stage models by other authors (e.g. Crawford, 1997) have realised 
that some of the stages might happen in parallel with varying levels of intensity in the 
stages. Hence, it can be speculated that such models are leaning towards the cross-
functional models. Cross-functional new product development models utilise the know-
how of people working in different departments of an organisation. According to the 
concept of Cross-Functional models, a high level of communication between different 
actors in the process enables the parallel occurrence or integration of the stages in the 
process of new product development (Trott, 2005, 402). The Concurrent Engineering 
models were also created to explain the simultaneous occurrence of different phases yet 
they do not place the importance of communication as high as does the Cross-
Functional models. 
 
Another way of explaining new product development is the Decision Stage models. 
According to Cooper & Kleinschmidt (1993), Decision Stage models explain new 
product development as a series of decisions taken along the process. These models bear 
similarity to the Activity Stage models in the sense that communication is an ongoing 
process including a high level of communication between the stages. Perhaps the most 
market-oriented models would be Response Models which concentrate on getting 
feedback from organisations or individuals about the new ideas before the initial new 
product development begins (Trott, 2005, 403). 
 
Already in 1967, Schon introduced the idea of Conversion-Process Model in new 
product development. He describes new product development as a conversion of inputs 
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from different sources into a substantial output; the product. Network Models illustrate 
a fairly similar view to this on how new products are being developed.  Network 
Models accept the idea of various sources being needed in order to be able to develop a   
new product. However, Network Models are slightly more specific on the sources 
businesses could use, than the Conversion-Process Models, stressing the impact of using 
not only internal, but also external sources in NPD. Trott (2005, 403) echoes the views  
of Conversion-Process Models and Network Models stating that NPD should be 
perceived as “a knowledge accumulation process requiring inputs from a wide variety of 
sources”. 
 
The NPD Models described in this chapter explained the different schools of thought on 
how new products are being developed. The Departmental Stage Models and 
Concurrent Engineering Models emphasised the expertise of the employees working in 
their specific fields, whereas Activity Stage, Cross-Functional, Decision Stage and 
Network Models placed the emphasis on high level of communication. The Conversion-
Process and Network Models highlighted the fact that sometimes also sources from 
outside of the company developing the new product might be needed, whereas the other 
models were more concentrated on the processes taking place within an organisation 
developing a new product. 
 
The development of new drugs requires the ability to use and explore life sciences 
combining theoretical models and frameworks with material resources and entities in a 
laboratory environment (Styhre, 2006). Still, in order to understand the complexities of 
new drug development, models such as Activity Stage Models and Cross-Functional 
Models, can break the process in stages making it easier to comprehend. 
 
New drug development incorporates the use of technology and science. Trott (2005, 18) 
defines science as “systematic and formulated knowledge” and advocates that 
“technology comes from employing and manipulating science into concepts, processes 
and devices”. Lynch (1988) elaborates stating that scientific work is not only 
discovering new objects, but requires “making such entities appear as immutable and 
ontologically stable, entities that can be tested and modified in laboratory practice.” 
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This concept depicts well the new product development process in the pharmaceutical 
industry described more in-depth in the following chapter. 
 
  
2.3. Understanding the Drug Development Process 
 
The process of drug development is more complex than traditional new product 
development process due to the integration of science and technology in the stages. 
Yelkur & Herbig (1996) define the steps of traditional new product development as idea 
generation, screening, concept development and testing, marketing strategy, business 
analysis, product development, market testing and commercialisation, in line with the 
activity stage model presented in the previous chapter. They also distinguish traditional 
new product development from the development process products aiming for global 
markets require, with the notion of the stages being integrated in the latter, opposed to 
the stage-by-stage approach.  
 
This distinction bears similarity to the new product development (NPD) process for 
pharmaceutical products by the means that although the NPD process is often described 
linear, the stages can sometimes overlap or happen in parallel. For instance, preclinical 
testing and development can sometimes be continued even though the clinical trials 
would have begun (Hine & Kapeleris, 2006, 191). Having the scientific knowledge to 
pursue the structured process of new drug development and understanding the 
regulatory environment which controls the process most of the way, are key factors in 
successful new product development in the pharmaceutical industry. 
 
Doranbje et al. (1998) lay the basis of new drug development on structured management 
procedures and factors such as novel forms of thinking, designing creative solutions to 
practical problems and coming up with new applications of knowledge that have been 
taken for granted previously. This view was also adopted by Sundgren & Styhre (2004) 
who state that the development of new drugs relies heavily on formal knowledge and 
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expertise in relevant scientific domains, for example medicine, pharmacology and 
biology.  
 
Personalised medicine is a fairly new approach to healthcare. Its main purpose is to 
match right patients with the right drugs using person‟s genomic information, in order 
to reach the highest levels of efficacy and safety possible. For personalised medicine 
drugs the new drug discovery and development processes are often accompanied with 
pharmacogenomics (PGx); applying genomic technologies in the drug discovery 
process or characterising existing drugs further (Barnes, 2007, vii). Integrating 
diagnostics, such as biomarker assays to a particular medicinal therapy can help to 
identify patients most likely to benefit from the treatment. Hence the term personalised 
medicine drugs covers both types; genomic-based drugs and combinations of 
therapeutics and diagnostics (Jain, 2009, 1).  
 
In literature on new drug development, small differences in the models of the process 
can be detected, yet the basic elements of the stages remain the same due to the basic 
technology behind the process and the highly regulated nature of the industry. Ginsburg 
& McCarthy (2001), distinguish the traditional linear model to drug development from 
the integrated model personalised medicine often uses. The traditional model begins 
from target discovery and validation, moving on to lead discovery and optimisation, 
followed by pre-clinical and clinical trials after which the drug sponsor would apply for 
marketing authorisation and introduce the new drug to the market. The traditional model 
can be seen fairly linear, even though some of the stages may happen in parallel.  
 
The integrated model differs from the traditional model in two ways. The stages in the 
model can either be exactly as in the traditional model, or the process can begin from 
pinpointing a gene that influences specific proteins in cells that are responsible for a 
disease developing, whereas in the traditional drug development model the process 
begins with identifying the disease causing proteins (target discovery). The other 
difference in the traditional and the integrated model is in the sequence the stages take 
place in. The integrated model is not linear but more of an ongoing cycle where the drug 
can be further improved even after it has been launched to the market by either by 
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redesigning the actual drug formula or by developing a diagnostic test to increase the 
medical benefits of the drug (FDA, 2010 [referred 7.7.2010]; Ginsburg & McCarthy, 
2001; Gupta et al., 2006; Hine & Kapeleris, 2006, 191-193; Styhre, 2006; Walsh, 1998, 
38). 
 
The NPD process of pharmaceuticals can be divided in three stages: research/discovery 
stage, development stage and commercialisation stage. Biotechnology is used in 
developing genomic-based drugs and biomarker diagnostic devices, which is why the 
emphasis in the NPD process of pharmaceuticals described in this thesis is on NPD of 
biopharmaceuticals. The following two chapters will describe the stages and the 
activities taking place during the stages in more detail.  
 
2.3.1. From Science to Product 
 
The process of drug development consists of the integration of scientific and 
technological knowledge. The whole process of drug development begins with 
discovering a new objective which will be developed into a new pharmaceutical. 
 
Drugs can be divided in two separate groups based on where they have been derived 
from: small-molecule drugs (SMDs) which includes new chemical entities (NCEs), also 
known as new molecular entities (NMEs); and biological drugs (Turner, 2007, 3). The 
term “biopharmaceuticals” can refer to biological drugs; drugs derived from biological 
sources (living organisms) or molecular entities that have been produced using 
biotechnology. Biological drugs are either protein- or nucleic acid- based (Walsh, 1998, 
2-3). To distinguish between the two in this study, in order to avoid confusion, the term 
biopharmaceuticals will be used to refer to NMEs produced using biotechnology and 
the term biological drugs to refer to drugs that have been derived from biological 
sources. Personalised medicine drugs can be both SMDs and biological drugs. 
 
The research/discovery stage constitutes of the activities of gene identification, target 
identification and validation, and lead identification. The Development Stage occurs 
after the discovery stage and includes the activities of lead optimisation, biological 
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testing and clinical testing (Figure 3). The Commercialisation Stage is the last stage in 
the NPD process and it includes applying for marketing approval from a regulatory 
authority and launching the product. The new product development process for 
pharmaceuticals is traditionally considered linear but stages can also occur in parallel.  
 
 
Figure 3 Drug Discovery and Development Process of Biopharmaceuticals 
 
Source: Based on Markiyannis & Biegel, 2004, 4 
 
The research/discovery stage for biopharmaceuticals includes various activities: gene 
identification, target identification and validation, and lead identification. Drug 
discovery of biopharmaceuticals uses typically a certain disease as a starting point, 
whereas traditional drug discovery would use treatment, hence skipping the disease 
gene identification stage, otherwise following the same model (Dennis & Gallagher, 
2001, 135; Hine & Kapelaris, 2006, 191).  
 
The first activity of the drug discovery stage is identifying a disease gene. The disease 
gene is a gene that affects specific proteins in cells which are responsible for the 
development of a disease. Dennis & Gallagher (2001, 135), define genes as an “ordered 
sequence of nucleotides located in a particular position on a particular chromosome that 
encodes a specific functional product”. Using the method of positional cloning, it is 
possible to identify disease genes of unknown biochemical function. Thus, a “disease 
model” is employed to identify relevant genetic or biological targets (Dennis & 
Gallagher, 2001, 123). In practice, this means finding the protein influenced by the 
already identified gene.  
 
The sequencing of the human genome has enabled the creation of an extensive pool of 
potential molecular targets which can be used to assist in the activity of identification. 
The drug targets are normally proteins (complex molecules, e.g. receptors for hormones 
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or specific enzymes) that are causing malfunctions in cells that consequently result in 
disease on individuals (Walsh, 1998, 41; Hine & Kapelaris, 2006, 191-193). When a 
target has been identified, it will need to be validated which means determining if the 
target is critically involved in the disease, and thus viable of being further developed. 
 
The next activity in the research/discovery stage is the lead identification which means 
finding lead(s), for instance molecules or chemical compounds, which interact with the 
identified target with the aim of inducing a desired therapeutic effect (Styhre, 2006). 
This interaction means the lead being capable of attaching itself to the target protein and 
starting to block the receptors or other active sites in the malfunctioning target. The lead 
molecule can be identified either with using the technique of high-throughput screening 
of a large library of chemical compounds, or natural products for biological drugs, or 
using the method of de novo design. De novo design means developing a novel lead 
molecule analysing the three-dimensional structure of the target molecule (Markiyannis 
& Biegel, 2004, 4). 
 
The Development Stage of NPD of pharmaceuticals can begin after the activities 
described in the discovery stage have been completed. The first activity in the 
Development Stage is optimisation of the identified lead. The lead can be optimised 
using biological testing and chemical synthesis (Markiyannis & Biegel, 2004, 4). The 
activity in the NPD of drugs that follows lead optimisation is preclinical development 
and testing. This includes various pharmacological analyses that examine the new drugs 
suitability to be moved on to the clinical research stage. Walsh (1998, 53) defines 
pharmacology as the study of the features of drugs and on the effect they have on 
humans. Preclinical development and testing are done on an animal model and includes 
various tests such as toxicity and mutagenicity tests that show whether the drug is safe 
to be tested on humans (Walsh, 1998, 53-55; Styhre, 2006). Mutagenicity tests are 
conducted in order to examine if the drug can damage DNA and are used mainly in the 
development process of chemical based drugs, whereas for biological products such 
tests can be performed after additional substances have been added to the drug 
formulation (Walsh, 1998, 55). 
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For personalised medicine drugs the new drug discovery and development processes are 
often accompanied with pharmacogenomics (PGx); applying genomic technologies in 
the drug discovery process or characterising existing drugs further (Barnes, 2007, vii). 
In the drug discovery phase, PGx can be applied with the attempt of discovering more 
efficient drugs; drugs designed to target specific genomic subgroups or drugs that target 
all subgroups.  
 
After the preclinical trials, the drug sponsor (research institutions, companies and other 
organizations responsible for the drug development) presents the findings of the 
preclinical trials to appropriate regulatory bodies, either the US Food and Drug 
Administration (FDA) in the US market or the European Medicines Evaluation Agency 
(EMEA) in the EU. However, often companies cooperate with regulatory agencies even 
before this point in order to be on the same page with the regulator on the requirements. 
For instance, in the USA an Investigational New Drug Application (IND) needs to be 
submitted to the FDA by the sponsor and if reviewed successfully, the clinical trials can 
start.  
 
The next activities of the Development Stage of the NPD process are the clinical trials. 
Clinical trials are divided in three phases and always happen in the sequence of Phase I, 
Phase II and Phase III. In the first phase of clinical trials, 20 to 80 clinical trials subjects 
are needed to participate in assessing safety of the drug in relation to dosage and side 
effects. In the first trial it is also common to research how the drug is metabolised and 
excreted.  
 
If the Phase I results are favorable the sponsor can move on to the next stage. Phase II 
trial, in which the data is gathered from 100 to 300 clinical trial subjects, establishes 
preliminary information on the efficacy of the drug and additional information on drug 
safety. Again, if the second phase is completed successfully, proving that the drug is 
effective in people who have a certain disease or medical condition, the development 
process can progress to the third phase of clinical trials.  
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The third phase requires the most clinical trial subjects with 1000 to 5000 people 
participating in the trial. The purpose of the Phase III trial is to test and compare the 
new pharmaceutical product with combinations of drugs or with an existing standard 
therapy, expand the knowledge already gained on the drug‟s safety and efficacy and to 
test the drug with different dosages and populations (Hine & Kapelaris, 2006, 191-193; 
FDA 2010[referred 7.7.2010]). Figure 4 depicts the stages of traditional drug 
development and also points out the stages in which PGx can be applied when 
developing personalised medicine drugs.  
 
Figure 4 Applications of PGx during Drug Development 
 
 
Source: Based on Kapeleris et al 2004; Webster et al, 2004 
 
Pharmacogenomics can be used in the lead identification phase to find allelic variants of 
drug target in order to discover drugs for specific genomic sub-groups. In clinical trials 
PGx can be applied in order to improve the safety and efficacy of new drug in 
development.  Recently, PGx has also been employed to improve safety and efficacy of 
already licensed drugs. The technology has helped further research on some drugs to 
segment patients to genomic subgroups to screen out those most likely to experience 
adverse drug reactions (ADRs). This has enabled drugs that have been restricted from 
being marketed due to severe ADRs in certain patient groups to access the market with 
PGx information added in the drug‟s label (Webster et al, 2004). 
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2.3.2. Regulations of Commercialising New Pharmaceuticals 
 
After the clinical trials have been conducted, the sponsor needs to apply for marketing 
approval for the drug. In the USA, the Food and Drug Administration (FDA) is 
responsible for reviewing Therapeutic Biologic Licence Applications (BLAs) for 
biological products and New Drug Applications (NDAs) for NMEs, both of which 
include all animal and human data, the analyses of the data and information on how the 
drug has been manufactured and its effects in the body. After the FDA has received the 
appropriate application, they have 60 days to decide if they find the information 
provided by the sponsor substantial enough to proceed reviewing it. According to the 
FDA‟s Center for Drug Evaluation and Research (CDER), 90 percent of standard drug 
NDAs are reviewed and acted upon in 10 months after the application has been 
received. (FDA 2010[referred 7.7.2010]). 
 
The FDA was established in 1930 and has been an official government agency as part of 
the US Department of Health and Human Services (DHHS) since 1988. The regulations 
given by the FDA are based upon the legislation from the Federal Food, Drug and 
Cosmetic Act (Walsh, 1998, 62). The agency operates in several fields which is why its 
functions have been divided in several departments. Besides CDER, the Center for 
Biologics Evaluation and Research (CBER) handles drug approvals, with in principle 
CDER evaluating small molecular drugs and CBER mostly biological drugs. However, 
the CDER sometimes reviews biological products as well.  The Center of Devices and 
Radiological Health (CDRH) is responsible for evaluating medical devices, for instance 
diagnostic tests, whereas the Center of Veterinary Medicine (CVM) and Center of Food 
Safety and Applied Nutrition (CFSAN) are specifically focused in animal drugs and 
food safety issues respectively (Walsh, 1998, 62).  
 
Whether it was the CDER or the CBER appointed to review the marketing application 
of a new drug, the review process is the same. The review team who conduct the 
primary review consists of experts of different fields such as chemists, medical doctors, 
pharmacologist and microbiologists who evaluate the studies conducted that ought to 
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establish the safety and efficacy of the drug. The review team also has the option of 
requesting additional information from the drug sponsor if they are not completely 
convinced by the sponsor‟s results and conclusions. In such cases, the FDA sometimes 
uses advisory committees which can give advice on the review team‟s concerns. After 
the primary review has been successfully conducted, the supervisors of the individuals 
in the primary review team will carry out a secondary review. If the FDA feels the drug 
sponsor has been able to prove that the drug gives a clinical benefit, it will be granted 
marketing approval (Walsh, 1998, 66-67; FDA 2010[referred 7.7.2010]). 
 
Since 1992, the FDA has been offering sponsors the opportunity of applying for a 
Priority Review which basically means that the time it takes for the review team to 
decide upon marketing approval is reduced to approximately six months (from the 
standard of ten months). However, Priority Review status is only given to drugs for 
serious, or also less serious, diseases that offer major advances in treatment or fill an 
unmet need in conditions where no adequate therapy exists. After receiving the request 
for Priority Review, the FDA has 45 days to decide whether a Priority or a Standard 
Review will be assigned for the drug in question (FDA 2010[referred 7.7.2010]). 
 
In 2004, with the attempt to integrate the adoption of personalised medicine and to 
transform the way pharmaceutical products are developed, evaluated, manufactured and 
used, the FDA launched the Critical Path Initiative (CPI). The initiative encourages 
using highly technologic tools such as nanotechnology and process analytic technology 
for manufacturers, and for companies to develop biomarkers and new assays to be used 
as companion diagnostics. For instance, the anti-coagulant drug Warfarin has had 
dosing information added to its drug label due to collaborative research conducted 
through the CPI (CPI update, 2010 [referred 12.7.2010]).  
 
Some PMDs are developed in parallel with a companion diagnostic, for instance while 
Genentech was developing its innovative drug Herceptin, indicated to treat HER2 
overexpressing breast cancer, the company set up a partnership with Dako to develop a 
companion diagnostic product; HercepTest (Genentech, [referred 20.7.2010]). The drug 
was designed to target HER2 (Human Epidermal growth factor Receptor 2) genes in 
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HER2 positive breast cancer, in which the cancer cells have an abnormally high number 
of HER2 genes in cells which cause the fast spread of the cancer cells. Herceptin is a 
biological therapy which targets these genes in order to stop the cancer cells from 
growing (Herceptin, 2010 [referred 20.7.2010]). Hence, HercepTest was designed to 
detect the overexpression of HER2 protein in breast cancer patients and thus can be 
used to assist physicians in finding out whether Herceptin is a suitable therapeutic 
option for a particular breast cancer patient (DAKO, HercepTest [referred 20.7.2010]).  
 
The regulations for medical devices in the US are fairly complex. Biomarker assays and 
other diagnostic products are classified into three groups by the FDA, depending on the 
indications for use and on the intended use. Furthermore, the classification is also based 
on the level of risk the device poses for patients with Class I including devices with the 
lowest risk and Class III those with the greatest risk. Class III medical devices require 
Premarket approval (PMA) from the FDA before being able to commercialise the 
product. The FDA describes Class III devices as products that “support or sustain 
human life, are of substantial importance in preventing impairment of human health, or 
which present a potential, unreasonable risk of illness or injury” (FDA, 2009 [referred 
21.7.2010]). 
 
For devices that belong to Class I or II (or exceptions in Class III) a 510(k) premarket 
notification submission is required to be filled to the FDA, instead of a PMA 
application. 510(k)‟s purpose is to demonstrate that the device is at least as effective and 
safe as an already legally marketed device that does not require a PMA. The CBER is 
responsible for reviewing both PMAs and 510(k)s. The review process for PMAs takes 
approximately 180 days, whereas the review for 501(k) clearance takes only 
approximately 90 days. However, albeit these set regulations, some IVD tests do not 
require any FDA clearance. Such tests are called Laboratory Developed Tests (LDTs) 
and are developed in a specific laboratory which also performs all testing. The 
requirements for tests to fit in this category are for the laboratory to be CLIA validated 
(comply with Clinical Laboratory Improvement Amendments) and to develop and 
perform tests in the laboratory‟s own facilities only. The FDA has also compiled a list 
of Class I medical devices that do not require 510(k) clearance or PMA. Still, the 
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manufacturers of these products are required to register their establishments (FDA, 
2009 [referred 21.7.2010]). 
 
In the European market, there are two pathways for drugs to gain marketing 
authorisation: the centralised procedure of the European Medicines Evaluation Agency 
(EMEA) or the Mutual Recognition Procedure (MRP) with which the application is 
evaluated by regulatory authorities in any of the member countries of the European 
Union. The EMEA has been operating since 1995 and it is located in London, England 
(Walsh, 1998, 69). 
 
The EMEA mainly evaluates novel and pioneering technologies. However, it does not 
evaluate pharmaceutical products directly but through two committees:  medicinal 
products for human use (the CHMP) and medicinal products for rare diseases (the 
COMP). The CHMP coordinates the evaluation of all technologically advanced 
products for human use with excluding those treating rare diseases and the 
COMP evaluates orphan medicinal products which affect no more than 5 in 10,000 
persons (Slater, 1997; Walsh 1998, 69-71). However, the EMEA does not distinguish 
new drug applications for biologicals and NMEs in the way as FDA does. 
 
The EMEA has set up the Pharmacogenomics Working Party (PgWP) in 2005 which is 
a team of experts that provide recommendations to the CHMP on issues related to 
pharmacogenomics. The agency defines pharmacogenomics as “the study of the 
variability of the expression of individual genes relevant to disease susceptibility as well 
as drug response at cellular, tissue, individual or population level” (EMEA, PgWP 
mandate, 2009[online, referred 20.7.2010]). The group was established in order to be 
able to improve the understanding and adoption of the new technologies 
pharmacogenomics offer which can be used in developing innovative drugs such as 
PMDs. 
 
After the drug sponsor has submitted their application for market approval in the 
centralised procedure, the EMEA has 10 days to give the initial appraisal stating 
whether the application is accepted for a review. If given a positive appraisal, the 
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application dossier will be sent to be appraised by a national authority in one of the 
member countries who will compile a report about the application. This report will be 
reviewed by the CHMP/COMP which issues a recommendation whether the drug 
should be approved or not. The review process should take approximately 210 days 
(Walsh 1998, 69-71). Drug sponsor can request for “accelerated approval” review 
which is similar to FDA‟s Priority Review. Accelerated approval can be granted to 
highly innovative drugs in order to speed up the review process which consequently 
brings the much needed drugs faster to the market. 
 
The last stage of gaining market authorisation in the European Union is for the 
European Commission to review the report written by the national authority in question 
and the recommendations made by the CHMP/COMP and decide if the drug should be 
granted market approval. The European Commission has 90 days to finish this process 
hence the total time the market authorisation should take is 300 days. However, it can 
be considerably more if one of the bodies involved request for additional information 
from the drug sponsor (Walsh 1998, 69-71). All information of the assessment process 
is publically available and published as EPARs (European Public Assessment Reports) 
on the EMEA website. 
 
The decentralised drug approval process, the Mutual Recognition Procedure, is used for 
products that do not qualify for an EMEA evaluation as well as for generic drugs and 
parallel imports. The Mutual Recognition Procedure issues a series of national 
authorisations based on the principle that EU Member States recognise each other‟s 
market authorisations. In order for a drug to be authorised, the drug sponsor must 
choose one of the member countries as its Reference Member State (RMS) of which 
national authority will conduct the initial marketing authorisation. The Mutual 
Recognition Facilitation Group will forward the initial authorisation to other Member 
States and if these Concerned Member States‟ (CMSs) national competent authorities 
approve it, the MRP is complete. The total duration of the MRP process is also the same 
300 days as is the duration for the centralised procedure. Sometimes the CMSs refuse to 
grant authorisation even though the RMS would have granted marketing approval. In 
such cases, the CHMP arbitrates (Walsh 1998, 69-71).  
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For medical devices, it is required to apply for CE mark in order to be able to 
commercialise a medical device in any of the member states of the European Union. 
There are four types of CE marks which when granted prove that the manufacturer or 
the particular product has signed the declaration of conformity, that is, the device 
complies with the EU directives set for a particular product group. The categorisation of 
devices is based on the level of risk associated to the product and the EU directives 
concerning it. The body responsible for authorising CE marks is the European 
Committee for Standardisation together with national standards authorities. For IVD (In 
vitro diagnostic) products the Directive 98/79/EC of the European Parliament and of the 
Council applies (EU Directive 98/79/EC, 1998, [referred 21.7.2010]). 
 
Once a drug has been granted marketing approval by the authority responsible for the 
market area, it can be launched. Launching a product means introducing the new 
product to the market and selling it in the market. 
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3.  METHODOLOGY  
 
The purpose of this study was to explore the regulatory environment of pharmaceutical 
industry in the US and EU, and also to analyse the impact it has on new product 
development of personalised medicine. To achieve this, the study was positioned as an 
exploratory research.  
 
Exploratory research approaches allow the researcher to open up new areas of a given 
phenomenon or a new phenomenon entirely (McQuarrie, 2006, 6). Using the method of 
exploratory research in this study does not only able the identification of relationships 
between different actors, the regulators and drug sponsors, but can also help to explain 
patterns related to the process of drug development and commercialisation (Robson, 
2002, 59). According to Saunders et al (2007,133), the three main methods of 
conducting exploratory research are searching relevant literature, interviewing experts 
of the field of interest and/or conducting focus group interviews.  
 
As such data collection was conducted by means of desk research. This means 
collecting secondary data from various sources such as books, research articles, 
corporate reports, online databases and websites of pharmaceutical companies, and 
industry related organisations. This method was chosen due to the vast amount of public 
data available on the subject of interest, such as case studies on regulations related to the 
process of developing and marketing drugs, and data on specific Personalised Medicine 
Drugs (PMDs) from the drug developing companies‟ websites and annual reports. 
 
As part of my studies in the Turku University of Applied Sciences, I did my internship 
for a company called Diaceutics which is a consulting firm specialised in personalised 
medicine. One of the research projects I assisted with was focused on the drugs I also 
chose to use in my “Case of Personalised Medicine” for this study. The drugs were 
chosen because they all are considered as PMDs and all have diagnostic tests 
identifying particular biomarkers, which can be used to assist with safety and/or 
efficacy issues related to the medicinal therapy.  
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In this study, the desk research data obtained was mainly statistical data, case studies 
and corporate reports. Data on the marketing authorisations was found from the 
websites of the FDA and EMEA, whereas data on the drugs and their development 
timeline was available on the drug developer‟s (or in some cases the company entitled 
to market the product) websites. For some drugs, such as Iressa and Herceptin, a whole 
website has been established with the attempt to increase the awareness and knowledge 
of patients and healthcare professionals on the drug.  
 
Generally, any data acquired without fieldwork is considered to be conducted by a desk 
research (Hague & Hague, 2004, 32-47). Google News Archive proved to be a very 
useful source of information. The archive consists of a large number of news articles 
that have been published in various newspapers or magazines all over the world and can 
be traced back several years, even decades. I used it for instance to obtain data on the 
drug and test launch dates in cases where the drug/test sponsor‟s website did not 
provide that information. Annual reports of pharmaceutical and diagnostics companies 
were used in addition to gather information on specific drugs and tests. Also, articles 
from magazines specialised in the pharmaceutical industry and biotechnology, were 
good sources of data offering the latest updates of products, technologies and changes in 
the regulatory environment. 
 
Desk research can be used as the sole means of data collection, like in this study, but 
also as part of data collection which includes the aspect of primary research. In such a 
case, desk research would be used to collect background information which would point 
out direction for the primary research or provide additional information (Birn, 2004, 
19). However, collection of primary data for this study was not necessary due to the 
nature of this research. 
 
The data was analysed by using content analysis. Stone et al (1966, 5) describe content 
analysis as “any research technique for making inferences by systematically and 
objectively identifying specified characteristics within text”. This approach was also 
accepted by Krippendorff (2004, 18) who defines content analysis as “a research 
technique for making replicable and valid inferences from texts, or other meaningful 
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matter, to the contexts of their use”. By other meaningful matter he refers to a whole 
variety of sources which should be considered: maps, sounds, works of art, images, 
symbols and numerical records. Furthermore, content analysis is empirically grounded 
and exploratory in process, combining mechanical and interpretative components 
(Krippendorff, 1980).  
 
Within the past decades, there has also been definitions varying quite extensively from 
Krippendorff‟s and Stone et al‟s ones. For instance, Berelson (1954, 489) related 
content analysis only to analyse the content of communication, providing a much 
narrower concept than Krippendorff and Stone et al after him. In respect to this study, 
Krippendorff‟s approach is most consistent with the type of data used. 
 
Thus, the analysis was conducted by dividing the gathered secondary data into 
categories from which it was in an interpretative manner decided which of the 
categories are most significant to the research objectives. In practise, the drugs chosen 
for the case study were segmented into categories based on the relationship the drug and 
test had in the development process and the importance the regulatory bodies have 
based on the tests. The time lapses were investigated in days for all of the objectives 
except for the time between drug launch and test launch which was measured in months. 
This was done since the exact launch dates for most of the tests were not available, but 
data was available for the month and year of the launch in most cases. The process of 
the analysis was reciprocal throughout and aimed to provide increased understanding 
and new findings of the process drugs go through before being commercialised. 
 
There were also some limitations to this study which were mostly related to the 
availability of data. Finding exact information on launch dates was difficult due to the 
complex nature of test regulations in the US and the fact that in Europe, drugs can be 
launched simultaneously in various countries or just in one country which consequently 
makes it difficult to find exact information. These limitations made the data collection 
and analysis more time consuming and complex. The limitations mentioned may also 
have affected the outcome of the research since the smaller the sample, the bigger the 
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possibility of errors. In this case, errors could mean generalising the phenomenon based 
on a relatively small number of examples.  
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4.  THE CASE OF PERSONALISED MEDICINES 
 
In this study ten personalised medicine drugs (PMDs) were analysed with the focus on 
the impact regulatory environments have on the drug approval and launch processes 
(Table 1). The selection criteria for the drugs were the use of pharmacogenomics (PGx) 
either in the development process of the drug or after the initial drug development to 
enhance its safety and/or efficacy, and also for the drug to have diagnostic test(s) 
available to identify specific biomarkers. The biomarker assays for the pharmaceuticals 
are used to assist with safety and/or efficacy issues related to the medicinal therapy. 
 
Table 1 Drugs and Indications 
Drug Name Drug Sponsor Indicated to Treat 
Herceptin  Genentech Cancer 
Erbitux  ImClone Cancer 
Selzentry/Celsentri  Pfizer HIV 
Vectibix Amgen Cancer 
Iressa AstraZeneca Cancer 
Ziagen  Glaxo Wellcome HIV 
Tarceva  Osi Cancer 
Tamoxifen  AstraZeneca Cancer 
Coumadin  BMS Coagulation 
Gleevec/Glivec Novartis Cancer 
 
Seven PMDs chosen for the case study are used to treat different types of cancer: 
Herceptin, Erbitux, Vectibix, Iressa, Tarceva, Tamoxifen and Gleevec. Two of the drugs 
included in the analysis have been developed to treat HIV infection; Selzentry and 
Ziagen, and one, Coumadin to treat blood coagulation. All of the drugs are described in 
more detail in the following chapter. 
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4.1. Product Descriptions 
 
Herceptin is a biological drug indicated for the treatment of HER2 overexpressing 
breast cancer, and was developed by Genentech. Biological drugs are derived from 
biological sources (living organisms) and can be either protein- or nucleic acid- based, 
whereas small-molecule drugs (SMDs) are chemical entities as described in Chapter 
2.3.1. Herceptin‟s active ingredient is trastuzumab.  
 
Erbitux is also a biological oncology drug like Herceptin and was developed by 
ImClone. The drug‟s active ingredient is cetuximab, and it is indicated to treat head and 
neck cancer, and also EGFR expressing metastatic colorectal cancer with the exception 
of patients with KRAS mutations in their tumors in codon 12 or 13. Amgen‟s drug 
Vectibix is used for the same indication in colorectal cancer. EGFR and KRAS are 
genomic biomarkers that have been detected to influence the efficacy of Erbitux and 
Vectibix in specific patient populations. Vectibix is the third biological drug analysed in 
this study and its active ingredient is panitumumab.  
 
Selzentry, developed by Pfizer, differs from the drugs mentioned above quite 
extensively. This is due to the fact that it is neither an oncology nor a biological drug 
but an SMD antiviral. Antivirals are drugs that are used to treat viral infections. The 
drug is marketed in Europe under the name of Celsentri, and is specifically indicated for 
treatment of adults infected with CCR5-tropic HIV infection. Its active ingredient is 
maraviroc. Another SMD antiviral included in this study was Glaxo Wellcome‟s Ziagen 
which active ingredient is abacavir. Ziagen is used for the treatment of HIV infection.  
 
Iressa and Tarceva are both SMDs indicated for patients with locally advanced or 
metastatic non-small cell lung cancer and were developed by AstraZeneca and Osi 
Pharmaceuticals respectively. Iressa‟s active ingredient is gefitinib and Tarceva‟s 
erlotinib. 
 
Tamoxifen is an oncology drug which was developed by AstraZeneca to treat metastatic 
breast cancer. The drug was already approved by the FDA in 1977. It was sold under 
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the brand name Nolvadex (tamoxifen is the name of the active ingredient) until 2006, 
when AstraZeneca pulled the drug out of the market due to increased generic 
competition after the patent of the drug had expired. 
 
Gleevec is also an SMD oncology drug and its active ingredient is imatinib.  The drug 
was developed by Novartis and is marketed as Glivec in the European market. The drug 
is indicated for the treatment of patients with Philadelphia chromosome positive 
myeloid leukemia (Ph+ CML) and also for patients with Kit positive gastrointestinal 
stromal tumors (GIST). Coumadin is the second older drug included in this study in 
addition to Tamoxifen; the FDA approved it already in 1954. The anticoagulant was 
developed by Bristol Myers Squibb and its active ingredient is warfarin. The drug is 
indicated for prevention and/or treatment of venous thrombosis and its extension, and 
pulmonary embolism (Drugs @ FDA [referred 26.7.2010]). Anticoagulants are generally 
used to prevent blood from clotting in veins. Table 2 lists all of the drugs used in this case 
study with their active ingredients. 
 
Table 2 Drugs and Active Ingredients 
Drug's Marketing 
Name 
Active 
Ingredient 
Herceptin  trastuzumab 
Erbitux  cetuximab 
Selzentry/Celsentri  maraviroc 
Vectibix panitumumab 
Iressa  gefitinib 
Ziagen  abacavir 
Tarceva erlotinib 
Tamoxifen  tamoxifen 
Coumadin warfarin 
Gleevec/ Glivec  imatinib 
 
Out of the ten drugs chosen for this case, three happened to be biological drugs; 
Herceptin, Erbitux and Vectibix. The rest of the drugs introduced above are SMDs. 
Figure 5 shows the distribution of Biological drugs and Small-Molecule Drugs used in 
the analysis.  
 TURKU UNIVERSITY OF APPLIED SCIENCES THESIS | Anna Elisa Suhonen  
 
40 
 
Figure 5 Breakdown of Drugs by Type 
 
 
The drugs were divided in three groups based on their innovativeness and the extent to 
which companion diagnostics are part of the medicinal therapy (Table 3). The level of 
innovativeness was assumed to be higher for drugs that have been developed parallel to 
a companion diagnostic. The reasoning behind this assumption is based on the high 
level of scientific and technological input in the drug discovery and development 
process required for developing targeted therapies. That is, matching the right patients 
with the most beneficial medicinal therapy.  
 
The criteria for a drug to be included in the group of Type A drugs was for the drug to 
be developed in parallel with a diagnostic test. Herceptin, Erbitux and Selzentry, were 
all developed in parallel with a companion diagnostic. The tests are required to be used 
prior therapy in order to establish whether the patient is likely to respond and thus 
benefit from the drug. The FDA and the EMEA have both stated that biomarker testing 
is mandatory for Herceptin and Erbitux, yet only the FDA has placed Selzentry under 
the mandatory biomarker testing status. This difference in the importance the two 
regulators have placed on a specific test can be caused by a variety of reasons. For 
instance, the differences in the procedures how medical devices are categorised and 
regulated in different markets can result in disparities in the global market. 
 
For a drug to be categorised as Type B, the test for the drug must have been declared 
mandatory by the EMEA and developed prior or after the drug in order to improve the 
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safety or efficacy of the medicinal therapy. The drugs that met these criteria were 
Vectibix, Iressa, Tarceva and Ziagen, all of which have mandatory biomarker testing in 
Europe but not in the US. The test for Ziagen is not to assist with efficacy of the drug, 
as the tests for the other Type B drugs, but to detect whether a patient is hypersensitive 
to the active ingredient of the drug, abacavir. Thus, the test is used to assist physicians 
making clinical decisions with the emphasis on the safety of the drug. 
 
The Type C drugs, Tamoxifen, Gleevec and Coumadin, are drugs for which a valid 
genomic biomarker has been identified, yet the biomarker testing is only recommended 
by the FDA and EMEA, not mandatory. For testing to be only recommended by the 
FDA and EMEA is usually due to insufficient clinical data proving a substantial benefit 
from using the product. The tests developed to be used with Coumadin are to provide 
information on how the patient metabolises the drug, which assists physicians when 
deciding upon a suitable dosage of the drug for individual patients. The tests for Tamoxifen 
and Gleevec have been developed to assist predicting efficacy of the drug in specific 
patients. Table 3 lists the drugs according to the Types described above.  
 
Table 3 Drugs Categorised According to Type 
Drug Type Type Description Products 
Type A  The drug was developed in 
parallel with a companion 
diagnostic 
 The testing is declared 
mandatory by the FDA and/or 
the EMEA 
 Herceptin 
 Erbitux 
 Selzentry/Celsentri 
Type B  There must be an available 
biomarker test  which has been 
developed to improve the 
efficacy or safety of the drug 
 The testing is declared 
mandatory by the FDA and/or 
the EMEA 
 Vectibix 
 Iressa 
 Ziagen 
 Tarceva 
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Type C  Biomarker test(s) available for 
the drug but testing is only 
recommended by the FDA 
and/or the EMEA 
 Tamoxifen 
 Coumadin 
 Gleevec/Glivec 
 
There are differences how significant the regulatory agencies find the usage of 
diagnostic devices in combination to pharmaceuticals. For example, out of the ten drugs 
the FDA has declared biomarker testing mandatory for three drugs; Herceptin, Erbitux 
and Selzentry, whereas the EMEA requires testing for six; Herceptin, Erbitux, Ziagen, 
Tarceva, Vectibix and Iressa.   
 
 
4.2. Application to Marketing Approval 
 
In order for a drug to be commercialised, it needs to be approved by the regulatory 
authority responsible for the market area. In the US, the FDA reviews all drugs and 
already in the application submission stage the drugs are divided in either biological 
drugs or small molecule drugs (SMDs). Drug sponsors hoping to get a biological drug 
approved must submit a Biologics Licence Application (BLA) to the FDA and if 
marketing approval is granted, the drug sponsor is free to launch the product in the US 
market. For SMDs the application requesting marketing approval is called New Drug 
Application (NDA). 
 
Table 4 outlines the type of application drug sponsors submitted to the FDA with the 
desire to be granted marketing approval. Herceptin, Erbitux and Vectibix are biological 
drugs hence the BLAs. The rest of the drug sponsors submitted NDAs due to the fact 
that the drugs are SMDs. All of the ten drugs, except for Tamoxifen and Coumadin 
went through the priority review process. The priority review process, discussed in 
Chapter 2.3.2, is an accelerated version of the standard review process and can be 
applied for innovative drugs that fall into specific categories the FDA has established. 
However, the reason why Tamoxifen and Coumadin did not go through the priority 
review process may not have anything to do with their level of innovativeness, but only 
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with the changes happened in the regulatory process within the past decades. That is, 
Tamoxifen was already approved in 1977 and Coumadin in 1954, and the priority 
review option was not introduced until 1992. 
 
Table 4 FDA Review 
DRUG Type of 
Application 
Type of 
Review 
Herceptin (Genentech) BLA Priority 
Erbitux (ImClone) BLA Priority 
Selzentry/Celsentri 
(Pfizer) 
NDA Priority 
Vectibix (Amgen) BLA Priority 
Iressa (AstraZeneca) NDA Priority 
Ziagen (Glaxo 
Wellcome) 
NDA Priority 
Tarceva (Osi) NDA Priority 
Tamoxifen 
(AstraZeneca) 
NDA Standard 
Coumadin (BMS) NDA Standard 
Gleevec/ Glivec 
(Novartis) 
NDA Priority 
 
 
The EMEA does not distinguish marketing applications for biologicals and SMDs in the 
way the FDA does. This is due to the differences in the procedures it takes for the 
regulatory authorities to grant marketing approvals. As described in Chapter 2.3.2, in 
Europe, there are two pathways for drug sponsors to apply for marketing approval, 
either the centralised procedure, or the Mutual Recognition Procedure (MRP).  
 
Depending on the type of process chosen, the authority responsible assigns the 
application to the review board specialised either in biological drugs or SMDs. A 
similarity the EMEA process bears to the FDA process is the different types of reviews, 
in terms of duration of the review, available. The EMEA calls the faster review process 
as the Accelerated Approval Process. 
 
All of the ten personalised medicine drugs went through the centralised review in the 
European Union. Selzentry was the only drug reviewed on the accelerated route. 
Another exceptional approval granted by the EMEA was for Gleevec which was given 
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Orphan drug status in the beginning of the approval process. To be categorised as an 
orphan drug, often speeds up the review process the same way as does the accelerated 
review. Since Orphan drugs are designed to treat a specific disease or medical condition 
that affects only a small patient population, they are often pushed to the market 
extremely quickly. This is because they are considered to offer major advances in 
treatment or fill an unmet need in conditions where no adequate therapy exists. 
 
Out of the ten drugs analysed in this study, data on the timeline between submitting the 
marketing approval application and gaining marketing approval was available for eight 
drugs. The data was unattainable for Tamoxifen and Coumadin. Figure 6 describes the 
distribution of the length the approval process took in Europe. The EMEA approval 
took between 300 to 400 days for 37 percent of the drugs. The duration of the approval 
process for 13 percent of the drugs was between 400 and 499 days, and for the 
remaining drugs the duration of the review was either between 250 and 299 days, or 
more than 500 days. 
 
 
Figure 6 Time Lapse between Application and Approval in EMEA Process 
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In comparison to this, Figure 7 shows the distribution of days the process took for the 
FDA. The number of days the FDA process took is considerably smaller than the 
number of days the EMEA process took. For only 13 percent of the drugs reviewed by 
the FDA the process took 250 days or more, whereas the EMEA review process took 
over 250 days for all of the drugs. For 12 percent of the drugs the number of days 
between submitting application to be granted marketing approval and actually gaining 
the approval was 50 to 99 days. For 37 percent of the drugs reviewed by the FDA, the 
process took between 100 and 149 days. 
 
 
Figure 7 Time Lapse between Application and Approval in FDA Process 
 
 
 
Type A Drugs 
 
Examining the time lapse between submitting application and being granted marketing 
approval, for Type A drugs specifically, the EMEA approval process took the longest 
for Herceptin. The process lasted 583 days. For Selzentry the duration of the process 
was 230 days and for Erbitux 182 days. On average the number of days it took for 
EMEA to approve a new drug was 405 days which makes Herceptin the only drug from 
this group to excel this.  
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For the FDA it took 230 days to grant Selzentry marketing approval and 182 days for 
Erbitux. Herceptin was the quickest to be approved by the US agency with only 144 
days which is below the FDA average of 166 days. Thus, the rank of the drugs to be 
approved by the FDA in terms of fastness is reverse in comparison with EMEA‟s. 
Between the two regulators, the largest difference in the time lapse of granting approval 
was for Herceptin, for which it took 419 more days for EMEA to approve the drug in 
comparison with the FDA. 
 
Type B Drugs 
 
In this category, Vectibix and Iressa were the drugs that exceeded the EMEA average of 
405 days to be granted marketing approval. For Vectibix the duration of the process was 
583 days and for Iressa 427 days. Tarceva and Iressa stayed below the average with the 
process lasting 388 days and 373 days respectively.  
 
For the FDA it took the longest to review Iressa with the process taking 276 days. The 
duration of the approval process for both Iressa and Ziagen, took longer than the FDA 
average of 166 days with the time lapse between application submission and gaining 
marketing approval being 176 days for Ziagen, and 276 days for Iressa as mentioned. 
Tarceva was the quickest to be granted marketing approval by the FDA with the process 
taking only 112 days. The FDA approval process took 138 days for Vectibix, resulting 
Vectibix being the drug in this group with the biggest difference in the time lapse of 
application submission and gaining marketing approval between the European and US 
regulators. It took EMEA 445 days longer to grant Vectibix marketing approval than it 
took the FDA to do the same. 
 
Type C Drugs 
 
The only drug belonging to Type C that data was available for was Gleevec. The drug 
was approved rather rapidly in both markets with the EMEA process lasting 255 days 
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and the FDA 72 days. All of the drugs and the time lapse between application 
submission and approval can be seen in table 5 below. 
 
Table 5 Time Lapse between Application Submission and Marketing Approval 
Type Drug Name Time 
lapse 
EMEA 
(days) 
Time 
lapse 
FDA 
(days) 
Difference 
between 
EMEA and 
FDA 
(days) 
A Herceptin 
(Genentech) 
563 144 419 
A Erbitux 
(ImClone) 
364 182 182 
A Selzentry 
(Pfizer) 
285 230 55 
B Vectibix 
(Amgen) 
583 138 445 
B Iressa 
(AstraZeneca
) 
427 276 151 
B Ziagen 
(Glaxo 
Wellcome) 
373 176 197 
B Tarceva (Osi) 388 112 276 
C Tamoxifen 
(AstraZeneca
) 
n/a n/a n/a 
C Coumadin 
(BMS) 
n/a n/a n/a 
C Gleevec/Gliv
ec (Novartis) 
255 72 183 
  Mean 405 166 239 
  Median 381 160             190                  
         
 
 
4.2.1. Summary 
 
It seems that the FDA process for granting marketing approvals is considerably quicker 
than the EMEA process. Gleevec was the fastest drug to be approved by both the FDA 
and the EMEA (Figure 6). The time lapse between submitting application and granting 
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marketing approval was only 72 days for the FDA and 255 days for the EMEA. 
However, it must be noted that there was quite a significant difference between the two 
regulators when comparing the duration of the process for Gleevec; the process took 
183 days longer for the European agency than the US agency. 
 
On average, the difference between the timeline of the reviews conducted by the EMEA 
and the FDA was 239 days. The largest differences in the time lapse between the two 
regulators granting marketing approval were for Herceptin and Vectibix, both of which 
are biological drugs. The smallest differences in the time lapse between the two markets 
were for Selzentry and Gleevec, both of which were accepted to be reviewed on the 
faster approval route in the US and the EU. The EMEA process for two out of the three 
biological drugs, took more than the average of 405 days. These drugs were Herceptin 
and Vectibix. For biological drugs reviewed by the FDA, only Erbitux stayed above the 
FDA average of 166 days, with the process lasting 182 days. 
 
Figure 8 Time between Application Submission and Marketing Approval for Each Drug 
 
 
Both Selzentry and Gleevec were given special review status by the EMEA which is in 
consistence with the two drugs being approved significantly faster than the rest of the 
drugs. All of the drugs approved by the FDA were given the priority review status 
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which explains the more modest differences in the timeline between all drugs in 
comparison to EMEA. 
 
 
4.3. Marketing Approval to Drug Launch 
 
Part of my objective in this study was to examine the time lapse from the moment a new 
pharmaceutical has been granted marketing approval until it is launched. Examining the 
time lapse between the stages of having been granted marketing approval and for the 
drug to be launched is more straightforward in the US market than in the European 
market. In Europe, once a drug is approved, it can be either launched in one country or 
in many countries simultaneously. Hence, for this study the United Kingdom (UK) has 
been chosen to represent the launch of pharmaceuticals in Europe. The UK was chosen 
for two reasons: the EMEA is located in the UK and the pharmaceutical market in the 
UK is one of the major European markets alongside Italy, France, Germany and Spain. 
The data for the time lapse between gaining marketing approval and launching a new 
pharmaceutical was available for seven of the drugs in the US market and for six in the 
European market. The data was unattainable for Tamoxifen, Coumadin and Ziagen in 
both markets and for Herceptin in the European market. 
 
For five out of seven drugs the time lapse between gaining marketing approval and 
launching the drug was less than 15 days in the US, whereas in the EU, for four out of 
six drugs, the number of days between approval and launch was over 15 days. It must 
be also noted that for none of the drugs examined in this case did the US launch take 
more than 35 days which could not be said of the European launches (See Figure 9). For 
two of the drugs the time lapse between approval and launch was over 35 days. 
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Figure 9 Time Lapse between Marketing Approval and Drug Launch by Region 
 
 
This difference can be caused by a variety of reasons. The US pharmaceutical market is 
more unite than the European market; even though member countries of the European 
Union have joint EU directives and regulations to follow, all countries have their own 
legislations which impact markets. Another reason could be the strategic approaches 
pharmaceutical companies follow when launching new products. For instance they 
might have one strategy for the US market but will need various different strategies for 
the European market since there are vast differences between the European countries. 
Thus, different approaches for each country might be required. 
 
On average, it took 13 days for drug sponsors to launch the newly approved 
pharmaceutical in the US market. In the European market the average was 27 days. 
Table 6 shows the number of days launching a new product after gaining marketing 
approval took for each of the drugs. 
 
Table 6 Time Lapse between Gaining Marketing Approval and Drug Launch 
Type DRUG USA (days) EU (days) 
A Herceptin  10 n/a 
A Erbitux  13 23 
A Selzentry/Celsentri  34 63 
B Vectibix  16 51 
B Iressa  14 8 
B Ziagen  n/a n/a 
B Tarceva  4 3 
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C Tamoxifen  n/a n/a 
C Coumadin  n/a n/a 
C Gleevec/Glivec 1 16 
  Mean 13 27 
 
Type A Drugs 
 
For Herceptin, the number of days between gaining marketing approval and launching 
the new pharmaceutical was 10 days in the US market. Data on its European launch was 
not available. For Erbitux, the time lapse was 23 days in the European market and 13 
days in the US market. In both of the markets, it took the longest for Selzentry to be 
launched after gaining marketing approval with the time lapse being 63 days in the EU 
and 34 days in the US. Thus, for both of the drugs data was available for both markets, 
the launching took longer in the European market. Selzentry was the only drug from this 
group for which the time lapse in both markets was larger than the EU average of 27 
days and US average of 13 days. 
 
Type B Drugs 
 
The time lapse between marketing approval and launch for Tarceva was almost the 
same in the EU and US markets; 3 days in the EU and 4 days in the US. For Iressa, the 
launching also took less time in the EU than in the US with the figures being 8 and 14 
respectively. The number of days between approval and launch was considerably longer 
for Vectibix in both markets, it took 51 days for the drug to be available in the EU 
market and 16 days in the US market. Thus, the time lapse for launching Vectibix 
exceeded both the EU average of 27 days and US average of 13 days. Also, for Iressa 
launching took a day longer than the US average. 
 
Type C Drugs 
 
Data was only available for Gleevec in this group. The time lapse between marketing 
approval and launch was 16 days in the EU and 1 day in the US, both of which are well 
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below the EU and US averages. Figure 10 shows the time lapse between gaining 
marketing approval and new product launch for each of the drugs.  
 
Figure 10 Time Lapse between Marketing Approval and Drug Launch for Each Drug 
 
 
 
4.3.1. Summary  
 
It appears that on average the drugs are brought to the market faster in the US than in 
the EU. The drugs launched the quickest in the US were Gleevec with only 1 day after 
gaining marketing approval, and Tarceva with only 4 days. In the EU, the drugs 
analysed for the same indicator were Tarceva with 3 days and Iressa with 8 days. The 
time difference between US and EU launch for Tarceva was only one day which stands 
out from the rest of the drugs quite significantly. For instance, the next drug with the 
smallest difference in days was Iressa with 6 days.  
 
The drugs that took the longest to be launched in both markets were Selzentry and 
Vectibix. Selzentry‟s launch took 34 days in the US and almost twice as long in the EU 
with 63 days. Vectibix was the second drug for which launch after gaining marketing 
approval took the longest with 16 days in the US and 51 days in the EU. However, the 
gap between the US launch of Vectibix and Iressa, which would have been the next in 
line with the most days launching the product took, was not as remarkable as the gap 
 TURKU UNIVERSITY OF APPLIED SCIENCES THESIS | Anna Elisa Suhonen  
 
53 
between the EU launch of Vectibix and Erbitux, with the number of days being 16 and 
13; and 51 and 23 respectively.  
 
It can be speculated that the differences in market environments in the US and EU result 
in pharmaceuticals being launched faster in the US market. In addition, the nature of the 
product may impact in the fastness the product is pushed to the market. For instance, the 
orphan drug Gleevec was commercialised within a day after gaining approval in the US 
market.  
 
 
4.4. Drug Launch to Test Launch 
 
The last part of my objective was to analyse the time lapse between the initial drug 
launch and launching a biomarker test for the drug. Some of the biomarker tests were 
launched in a similar way as pharmaceuticals; first applying and gaining marketing 
approval, after which commercialising the product is legal. However, since the 
regulatory environment, described in further detail in Chapter 2.3.2, is rather complex 
for medical devices, it must be mentioned here that some of the tests cannot be launched 
for commercial purposes, depending on the classification of the product. These tests are 
the Laboratory Developed Tests (LDTs) which can only be used in the laboratories 
where they were developed and hence not sold as test kits to be used elsewhere. 
 
For some of the drugs a number of tests are available which is why for this objective the 
first test commercialised suitable for detecting the biomarker appropriate for a particular 
drug was chosen (Appendix 1). For some of the drugs the same tests can be used since 
they have the same target protein in the tumours, located in the same part of the body. 
For instance, the same test, Dako EGFR PharmDx Kit, can be used to test for EGFR 
expression in tumours for patients with colorectal cancer in order to establish whether 
the patients are likely to benefit from Erbitux and Vectibix therapies.  It has also been 
discovered that patients with KRAS gene mutations are unlikely to respond to Erbitux 
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and Vectibix which is the reason there are two separate tests, EGFR and KRAS, for 
these drugs.  
 
However, there is an extensive difference in how the US market and the European 
market regulate KRAS testing. In Europe, there are KRAS tests such as the DxS 
TheraScreen KRAS which is CE-marked and commercially available, whereas in the 
US there are no FDA regulated KRAS tests but only LDTs. LDTs cannot be launched in 
the device market but only be used in the laboratories that have developed them. Thus, 
in the analysis of the time lapse between drug and test launch, both of the biomarkers 
have been taken into account even though no data is available on KRAS test launches in 
the US market for obvious reasons. Table 7 lists the drugs with their biomarkers and 
tests used in the analysis. 
 
Table 7 Drugs and Tests Based on Biomarkers 
Drug Name Valid Genomic 
Biomarker 
Diagnostic Test for the 
drug available in the 
US market 
Diagnostic Test for the drug 
available in the EU market 
Type A 
 Herceptin 
 Erbitux 
 
 
 Selzentry/ 
Celsentri 
 
 HER2+ 
 EGFR+/K
RAS 
 
 CCR5 
 
 HercepTest 
 Dako EGFR 
PharmDx/KR
AS LDTs 
 Monogram 
Trofile 
 
 
 HercepTest 
 Dako EGFR PharmDx/ Dxs 
TheraScreen KRAS 
 
 Monogram Trofile 
Type B 
 Vectibix 
 
 
 Iressa 
 
 Tarceva 
 
 Ziagen 
 
 
 EGFR+/K
RAS 
 
 EGFR – 
 
 EGFR- 
 
 HLA-
B*5701 
 
 Dako EGFR 
PharmDx/KR
AS LDTs 
 Genzyme 
EGFR 
 Genzyme 
EGFR 
 LabCorp 
HLA-B5701 
 
 Dako EGFR PharmDx/ DxS 
TheraScreen KRAS 
 
 DxS TheraScreen EGFR 
 
 DxS TheraScreen EGFR 
 
 Delphic HLA-B5701 
Type C 
 Tamoxifen 
 
 
 Coumadin 
 
 
 
 
 Gleevec/ Glivec 
 
 CYP2D6 
variants 
 
 CYP2C9 
& 
VKORC1 
Variants 
 
 C-Kit 
 
 Roche 
Amplichip 
 
 PGx Predict 
Warfarin 
 
 
 
 Dako C-Kit 
PharmDx 
 
 Roche Amplichip 
 
 
 n/a 
 
 
 
 
 Dako C-Kit PharmDx 
 TURKU UNIVERSITY OF APPLIED SCIENCES THESIS | Anna Elisa Suhonen  
 
55 
 
To examine the time lapse between drug launch and its biomarker test launch data was 
available for eight drugs in the US market and seven drugs in the EU market. The drugs 
data was unattainable for were Tamoxifen and Coumadin in both markets and Ziagen in 
the European market. The time between drug launch and test launch was measured in 
months since the exact launch dates for most of the tests were not available, but data of 
the month and year of the launch in most cases could be found. It can be seen from 
Figure 11 that in the US, two drugs were launched the same month as their tests. These 
drugs were Herceptin and Erbitux. Figure 11 shows the time lapse between drug 
launches and test launches in months. 
 
Figure 11 Time Lapse between Drug and Test Launch by Region 
 
 
 
In Europe, one drug was launched the same month as its test which was Vectibix. The 
drugs that had a test launched a month before or after the drug were Herceptin in the EU 
and Selzentry in both markets. In the US and the EU, for one drug it took between 2 and 
24 months for the test to be available. This drug was Tarceva. For the rest of the drugs, 
the time lapse between the drug being launched and the test being launched (in either 
order) was over 25 months.  
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Type A Drugs 
 
Herceptin, Erbitux and Selzentry were all launched either on the same month as the 
companion diagnostic tests or a month after the test launch in the US market. This was 
expected since the products had been co-developed. In the European market the findings 
appear similar with the exception of the KRAS testing for Erbitux which was available 
42 months after the launch of the drug. This difference can be explained with the fact 
that the drug‟s companion diagnostic was the Dako EGFR PharmDx Kit, and the KRAS 
testing was developed afterwards. Thus, it can be said that both in the US and in the EU 
all Type A drugs were launched within a month from their companion diagnostics. 
 
Type B Drugs 
 
Vectibix stands out considerably from the rest of the drugs since in the US, the EGFR 
test was launched almost 3 years earlier than the drug, whereas the KRAS test was 
launched at the same time as the European launch of the drug. As mentioned earlier, the 
same EGFR test can be used for both Erbitux and Vectibix and since Vectibix was 
launched 32 months after Erbitux, by this time the KRAS test had been developed. The 
DxS TheraScreen KRAS test had been CE-marked and launched in Europe the same 
month as Vectibix was launched.  
 
The same biomarker tests can be used for Tarceva and Iressa. Iressa was launched 
before Tarceva in the US which is why the time lapse before the test was available was 
only 10 months for Tarceva and 28 months for Iressa. However, in the European 
market, the order for the launch of these two drugs was reverse. Thus, the number of 
months between drug launch and test launch in the European market was 19 for 
Tarceva. In Iressa‟s case, the appropriate test had already been in the market 27 months 
before the drug (Table 8). 
 
The drug for which the time lapse between drug launch and test launch was the longest 
was Ziagen, with 71 months the drug being on the US market before the test. The nature 
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of the test can explain this. The HLA-B*5701 biomarker test is designed to detect those 
patients who are hypersensitive to Ziagen and thus unsuitable to be treated with the 
medicine. Often such issues cannot be detected in the initial clinical trials but after the 
drug has already been in the market. Moreover, a specific need for a diagnostic product 
was developed and after the test is commercialised, it can be used to increase safety of 
using the specific drug. 
 
Type C Drugs 
 
The only drug in this category for which data was available for was Gleevec. The 
biomarker test for Gleevec was launched 33 months after the drug‟s launch in the 
European market, and 49 months after the drug‟s US launch. 
 
Table 8 Time Lapse between Drug Launch and Test Launch in Months 
Drug Name of Tests 
launched in the 
US  
Name of Tests 
launched in the 
EU 
Months between 
drug and test 
launch in US 
Months between 
drug and test 
launch in EU 
Herceptin HercepTest HercepTest 0 -1 
Erbitux  Dakocytomation 
EGFR pharmDx 
test kit 
Dakocytomation 
EGFR pharmDx 
test kit 
0 n/a 
  KRAS Laboratory 
developed tests 
DxS TheraScreen 
KRAS 
n/a 42 
Selzentry/
Celsentri  
Monogram Trofile  Monogram Trofile  -1 -1 
Vectibix Dakocytomation 
EGFR pharmDx 
test kit 
Dakocytomation 
EGFR pharmDx 
test kit 
-32 0 
  KRAS Laboratory 
developed tests 
DxS TheraScreen 
KRAS 
n/a 0 
Iressa Genzyme EGFR DxS TheraScreen 
EGFR 
28 -27 
Ziagen Labcorp HLA 
B5701 
Delphic HLA B5701 71 n/a 
Tarceva  Genzyme EGFR DxS TheraScreen 
EGFR 
10 19 
Tamoxifen  Roche Amplichip  Roche Amplichip n/a n/a 
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Coumadin  PGx Predict 
Warfarin 
n/a n/a n/a 
Gleevec/Gl
ivec 
DakoCytomation C-
Kit PharmDx 
DakoCytomation C-
Kit PharmDx 
49 33 
Mean     16 8 
 
 
4.4.1. Summary 
 
It can be seen that for all the biological drugs; Herceptin, Erbitux and Vectibix, a test 
was available straight after the drug was launched. For all Type A drugs, tests were 
commercialised either a month before or simultaneously with the drug. In general, the 
time lapse between launching the drug and test was longer for Type B and C drugs. 
 
Table 8 shows clearly that the timeline between the drug launch and the test launch was 
on average shorter in the EU than in the US. The negative numbers depict the number of 
months the test was launched before the drug. It can be assumed that the differences in 
the way medical devices are regulated in the two markets may have an impact on the 
speed tests are commercialised; the regulations for devices are more straightforward in 
the European market.  
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5.  DISCUSSIONS AND CONCLUSIONS 
 
The objective of this study was to analyse the regulatory requirements of the USA and 
EU at different stages of drug development process. The research questions assumed 
differences in the regulatory regimes of the USA and EU and that the differences might 
be significant in the new drug development process. In this chapter the implications 
between the theoretical framework of new product development and personalised 
medicines will be discussed, in addition to conclusions and recommendations on how 
the findings of this study can be used in assistance of making managerial decisions in 
the corporate world. 
 
 
5.1. Theoretical Discussions  
 
Three streams of literature were reviewed to gain theoretical insight in the processes 
taking place while commercialising personalised medicines; Innovation and New 
Product Development, and New Drug Development. The theories were chosen to gain 
further understanding on the highly structured process of drug development controlled 
by scientific, technological and regulatory aspects. 
 
 It was found that the description of the term innovation has evolved in the past 40 years 
from being considered merely as an idea or a process causing change to the widely 
accepted definition of a new concept needing to be successfully developed and 
commercialised in order to become an innovation (Abernathy & Utterback, 1978; Trott, 
2005, 17). Innovation Development theories were included in this research in order to 
explain the concept of innovation and especially how new products are developed and 
commercialised. 
 
 The literature on innovation theories by different authors defined different types of 
innovations according to the fields of their interests, for instance Schumpeter (1964, 59) 
segmented innovations into being either an introduction of a new commodity or 
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production method, opening of a new market, changing the source of supply or 
reorganising an industry. In literature on technological innovation, the term was used to 
describe the process a new product goes through starting from the idea generation, 
moving through the development of the product with the help of sciences into a 
finalised item (Styhre 2006; Cantisani, 2005). 
 
The study also took interest in the different models of how innovations develop from 
being abstract ideas into actual commercialised products. The technology push, market 
pull models, and the simultaneous coupling model (Chapter 2.1.2.) all identified 
manufacturing, marketing and R&D as the three functions that support the birth of 
innovation. As described in Chapter 2.1.2. the technology push and market pull models 
are both linear with the technology push model starting from the  R&D stage, moving 
on to the manufacturing stage and ending in the marketing stage, whereas the market 
pull model begins with marketing, after which a new product is developed and 
manufactured. The simultaneously coupling model does not state the exact starting 
point of innovation but accepts the idea of the same stages taking place in the process 
(Trott, 2005, 22-24, Schumpeter, 1964, 58-62). In addition to how innovations come 
alive, the theory of how individuals adopt innovations was described. The diffusion of 
innovation theory by Rogers (1962, 2003) was mentioned with the attempt to 
understand this phenomenon.  
 
The theories of new product development (NPD) and drug development were reviewed 
to gain further understanding of the stages and factors affecting the development of 
PMDs. Yelkur & Herbig (1996) described the stages of new product development 
involving generating a new idea, developing a concept based on the idea, manufacturing 
a product and creating a business strategy around it. Chapter 2.2 also described the 
various models created to describe the stages NPD involves.  
 
The Drug Development process, though not a theory in itself, was used to provide a 
framework to understand about the chemical and microbiological stages of developing 
and commercialising drugs. Even though my research did not cover all the processes 
and aspects of these theories mentioned above, they helped set the stage for isolating the 
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post invention commercialisation of new drugs. 
 
It was explained in chapter 2.3 that the NPD process of pharmaceuticals is divided in 
three stages: research/discovery stage, development stage and commercialisation stage. 
The research and development stages described the scientific and technologic aspects of 
developing a new drug, while the commercialisation stage was focused on the 
regulations set by the FDA and EMEA (regulatory agencies of the United States and 
European market areas). For the data collection of the case study, only the theory of 
commercialising a new pharmaceutical was relevant. The rest of the theories could not 
be used in the case itself but were reviewed to deepen the understanding of the process 
before the commercialisation phase. 
 
Chapter 2.3.2 described the regulatory processes of commercialising new 
pharmaceuticals in the US market and the European market. The US market is regulated 
by the Food and Drug Administration (FDA) and the European market by the European 
Medicines Evaluation Agency (EMEA). It was found that description of the regulatory 
processes of drug commercialisation supports the actual impact regulatory bodies in the 
innovation system have in the commercialisation of new pharmaceuticals. The role the 
FDA and EMEA have in the innovation process is enormous. As mentioned in chapter 
2.3.1 the extent of collaboration between drug sponsor and the regulator does not only 
limit to the review process of marketing approval but begins already before the start of 
clinical trials. The regulations set by the FDA follow the drug development process 
starting from submitting the investigational new drug (IND) application to the FDA 
after preclinical trials in order to get clearance to start clinical trials on humans. The 
regulatory agencies have been established to make sure the pharmaceuticals that are 
available for consumers are safe to use. However, it must be mentioned that hardly any 
drugs are 100 percent safe for all patients which is why in the pharmaceutical industry 
the term safe is used to describe a drug which benefits outweigh its possible negative 
side effects.  
 
One of the key findings of the impacts the regulatory regimes the US and EU market 
have on the development process of personalised medicine drugs was that the Priority 
 TURKU UNIVERSITY OF APPLIED SCIENCES THESIS | Anna Elisa Suhonen  
 
62 
Review route established by the FDA to speed up the process of commercialising new 
innovative drugs was used when reviewing the PMDs approved after the Priority 
Review initiative was established in 1992. This shows that the FDA is encouraging 
pharmaceutical companies to develop innovative drugs and is interested in helping the 
fast commercialisation of the new drugs. It was also found that the PMDs reviewed by 
the EMEA took considerably longer to be commercialised in the European market. It is 
assumed this is because of the slower process of the European agency and the 
differences in the market environment of the US and EU. The process on regulating the 
commercialisation of drugs (chapter 2.3.2.) described how the EMEA has also 
established a faster route of reviewing innovative drugs, the accelerated approval. 
However, it was found that the accelerated route was only applied to one of the ten 
PMDs. Consequently, the review process took much longer in the European market in 
comparison to the US market. 
 
 
5.2. Conclusions 
 
The desk research conducted revealed that there are vast differences in the processes 
and regulations the FDA and EMEA have set for pharmaceuticals and medical devices. 
These differences influence the speed in which new drugs are brought to the market. For 
personalised medicine drugs (PMDs), it seems that the drug development process is 
very much influenced by the same scientific, policy and market forces as for the rest of 
the pharmaceutical industry. However, it appears that especially in the US market, 
which is regulated by the FDA, PMDs are given priority review status, meaning the 
drugs are reviewed quicker than normally. It can be assumed that the reason for 
speeding up the review process is a result of a mutual understanding by the regulatory 
agency and drug sponsors of the importance of making new innovative drugs available 
for patients as soon as possible.  
 
It was found that the development process of PMDs is likely to follow the integrated 
model of new product development. The model describes the NPD process as several 
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sequential stages, some of which may occur in parallel, and the process can be an 
ongoing cycle of constant development instead of being linear (Ginsburg & McCarthy, 
2001). For instance, a pharmaceutical can be further improved even after it has been 
launched to a market by either redesigning the actual drug formula, narrowing down the 
patient group taking the drug to genomic sub-groups or by developing a diagnostic test 
to increase the medical benefits of the drug. In addition, analysis of the ten personalised 
medicines showed that pharmacogenomics (PGx) was applied either during the NPD 
process of the drugs or after the launch of the drug, in line with Webster et al‟s (2004) 
description of application of PGx in NPD process.  
 
The application of the integrated model and PGx can be detected from how some of the 
drugs were developed parallel to a companion diagnostic (Herceptin, Selzentry and 
Erbitux), how for some of the drugs diagnostic tests were developed after the drug had 
been on the market for some time (Ziagen, Tarceva, Iressa, Gleevec), and how PGx 
information has been added to the drug‟s label years after its initial launch with the 
purpose of increasing the safety of the drug (Coumadin).   
 
According to the analysis conducted, the number of days between submitting marketing 
approval application and gaining approval was less in the US than in the EU. Gaining 
marketing approval from the EMEA took 405 days on average for the PMDs analysed 
in this study, which was 95 days more than the 300 days EMEA has set as its target 
duration of the review process. This reveals that at least with this sample of drugs the 
EMEA failed to achieve its target. All of the drugs which were reviewed by the FDA 
were reviewed using the priority review process and on average took 166 days. The 
FDA has set 180 days as its target to review drugs with priority status which was clearly 
achieved with these PMDs. In conclusion, the review process took the European agency 
239 days longer than the US agency. 
 
The EMEA reviewed two drugs under a special status; Selzentry on the accelerated 
route, and Gleevec as an orphan drug. It could be detected that for both of the drugs the 
review took less than 300 days (285 and 255), which was considerably less than the 
average of 405 days. Thus, it seems the accelerated route or orphan status actually 
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accelerates the process as it is supposed to even though the normal route of approval 
takes longer than the European agency‟s target.  
 
The time lapse between gaining marketing approval and launching a new 
pharmaceutical was also shorter in the US than in Europe. Therefore, it could be 
concluded that the whole process of commercialising a new pharmaceutical product 
happens faster in the US than in Europe.  
 
The reason behind the difference in the time lapse of commercialising (time from 
submitting marketing approval until launching a new product) new pharmaceuticals in 
these two markets could be described multilayered. Obviously, the way how the 
regulating agencies handle the marketing authorisation process has the most remarkable 
influence in the speed of commercialising new pharmaceuticals. Their processes are 
again influenced by the overall market environment they operate in and the issues on the 
agenda of the policy makers in that specific market area. As market environments, the 
US and EU are very different. For instance, the EU market is bigger in size and more 
heterogeneous. Since the European Union consists of different countries, it can be 
assumed that the level of bureaucracy is higher when the legislation and regulations of 
individual countries have to be taken into account as well. Not to mention how the 
EMEA marketing authorisation process involves more parties (the EMEA, national 
authorities, European Commission)in comparison to the more centralised structure of 
the FDA.  
 
It was found that the time lapse between a drug and its biomarker test being launched 
was shorter in the European market than in the US. It can be assumed that the reason 
behind this is closely related to the emphasis the regulatory agencies of the two market 
areas have placed on biomarker testing. Diagnostic tests for six of the ten drugs were 
declared mandatory by the EMEA, whereas biomarker tests for only three of the drugs 
were set mandatory by the FDA. This discrepancy is probably also a result of how 
marketing diagnostic devices is regulated in the two markets, which again is connected 
to the level of significance the two regulators have set for combining diagnostics with 
therapeutics.  
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Another factor which may have an impact in the speed in which newly developed 
PMDs are pushed to the market is the rareness of the disease or medical condition the 
drug is designed to treat. For instance, the orphan drug Gleevec was commercialised 
within a day after gaining marketing approval in the US market (orphan drugs are 
designed to treat diseases or medical conditions affecting only 5 individuals in 10000). 
However, further research on this aspect would be required since Gleevec was the only 
orphan drug included in this case study. In addition, it would be interesting to know 
whether the drugs that fill an unmet need in the market, such as Gleevec, are 
commercialised faster in comparison to drugs that have been developed to treat patients 
in illnesses and/or medical conditions for which some sort of therapy already exists. 
 
 
5.3 Managerial Implications 
 
From a managerial point of view, the findings of this thesis can give ideas on which 
market should a pharmaceutical and/or diagnostics company launch their new product 
in first. Since developing new pharmaceuticals and medical devices is an extremely 
time-consuming process that costs millions of dollars or euros, it is expected that the 
companies want the new products out in the market as soon as possible in order to start 
gaining revenue.  To achieve this, and to avoid unnecessary costly delays, managers 
have to be very familiar with the policies of the regulatory agencies. 
 
As mentioned, the overall process of commercialising new PMDs was faster in the 
United States than in Europe. In the US, on average the number of days between drug 
sponsor submitting marketing approval application and launching a new product was 
179 days. The comparable figure for EU was 432 days. Also, for most of the PMDs the 
faster review route designed for highly innovative drugs was used in the US but not in 
Europe. On one hand, this could give an insight of aiming to launch a new PMD first in 
the US market in order to start making sales while waiting for the EU marketing 
approval and creating marketing strategies for the European countries the drug sponsor 
wants to launch the new PMD in. On the other hand, since discovering and developing a 
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new drug might take ten years, one might wonder whether this difference of merely 
eight and half months is significant. 
 
It must be mentioned that whilst making decisions on which market should one launch 
their product in first, there are issues such as policies of healthcare authorities and 
reimbursement of cost of drugs that a manager should look into in addition to the 
regimes of the FDA and EMEA. Since pharmaceuticals for serious diseases are usually 
extremely expensive, welfare countries establish policies on how much of the state‟s 
budget allocated to healthcare can be used to pay part of the costs related to treating its 
citizens. Nevertheless, the whole aspect of reimbursing pharmaceuticals is such a wide 
topic that another research would have to be conducted in order to look into that aspect 
in the managerial decision-making of choosing the first launch country for a new 
product. 
 
It was found that the time lapse between gaining marketing authorisation and launching 
a new PMD was on average 14 days quicker in the US than in the EU. What may cause 
the delay for companies of launching new pharmaceuticals in the European market is 
the size of the distribution channel that expands over country borders, whereas in the 
United States the distribution channel is most likely more homogeneous with fewer 
parties involved in the process. It can be assumed that the size of the market and number 
of actors involved in the commercialisation process of a new product has a direct impact 
in the time the procedure takes.    
 
The aspects mentioned above taken into consideration, it is recommended that managers 
should make the decision on which market to commercialise a new pharmaceutical in 
first, based on the level of innovativeness the regulator places on that particular drug 
type. This recommendation is reasoned with the finding that for the PMDs analysed in 
this research, the FDA reviewed most of them with the faster review process which is 
specially designed for highly innovative drugs but the EMEA used the standard review. 
Thus, it seems that the US regulatory regime is more favourable towards highly 
innovative drugs than the European regime, making the US market the better option to 
commercialise a new drug in first. 
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It is also recommended that managers of pharmaceutical companies should concentrate 
on keeping the communication flow between the company and the regulatory bodies 
ongoing through the whole development process of new drugs. If the level of 
communication is high throughout the process, it is more likely that the marketing 
approval review happens faster and consequently the pharmaceuticals can be launched 
in the chosen market quicker. 
 
Whereas launching a new PMD was faster in the US, the time lapse between a drug and 
its biomarker test being launched was shorter in the European market. In addition, six 
out of the ten drugs analysed had biomarker tests that EMEA had declared mandatory to 
use in combination to the therapeutics, in comparison to the FDA only demanding three 
of the drugs to be accompanied with the tests. Thus, this finding shows that the 
European market is more favourable market area for diagnostics companies who operate 
in the field of personalised medicine.  
 
The status the regulatory agencies set for diagnostic devices is significant in their 
commercial success. It can be presumed that if conducting biomarker testing before 
starting medicinal therapy is mandatory, the adoption rate of physicians prescribing 
testing is higher. Consequently more tests are being sold.  Hence, it can be concluded 
that such a regulatory environment that encourages the usage of biomarker testing 
would be more appealing to diagnostic companies. 
 
Knowing that there are differences in the regulatory regimes of the US and European 
market and that these differences impact the commercialisation process of new PMDs 
can help managers to improve their own performance and consequently the company‟s 
performance. Having the knowledge of the scientific and technological aspects taking 
place during new drug development and understanding the complexities of the market 
has a direct influence in managers‟ capabilities in making informed decisions. At the 
end of the day, the pharmaceutical industry exists to improve and maintain the well-
being of humans and it seems that the personalised medicine approach is especially 
emphasising the application of state-of-the-art technologies to improve the quality of 
healthcare. 
 TURKU UNIVERSITY OF APPLIED SCIENCES THESIS | Anna Elisa Suhonen  
 
68 
5.4 Implications for Future Research 
 
It was learned that the process of developing new personalised medicines is influenced 
by the same scientific, policy and market forces that shape drug development in other 
areas of the pharmaceutical industry. However, it seems that the regulatory policies and 
pharmaceutical industry in general is trying to encourage the application of personalised 
medicine in new drug development. 
 
The topic of this research was extremely wide and was narrowed down with the 
research questions set in the beginning of the research process. The research conducted 
could have been much further expanded with using a bigger sample of drugs or using 
completely different research methods, for instance adding the aspect of primary 
research by interviewing drug sponsors or regulatory bodies.  
 
If this research was continued, I would like to add the element of reimbursement to the 
commercialisation process. As mentioned, whether a drug is being reimbursed in the 
target market can have a significant impact in its commercial success. Thus, it would be 
extremely useful to look more deeply into that aspect in addition to the regulatory 
regimes impacting the process. 
 
In addition, it would be interesting to know whether the make of the drug, in terms of 
whether the drug is a biological drug or a small-molecule drug (SMD), has an impact in 
the timeline of its commercialisation. However, for this to be discovered, the sample 
group would need to have an equal amount of biological drugs and SMDs.  
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APPENDIX 1 
 
 
Appendix 1 Drugs and Tests in Both Markets According to Biomarker 
Drug 
Valid Genomic 
Biomarker 
Diagnostic Test 
available in the US 
Diagnostic Test 
available in the EU 
Herceptin HER2 + HercepTest HercepTest 
Erbitux  EGFR + 
Dakocytomation 
EGFR pharmDx test 
kit 
Dakocytomation 
EGFR pharmDx test 
kit 
  KRAS KRAS LDTs 
DxS TheraScreen 
KRAS 
Selzentry/ 
Celsentri 
CCR5 Chemocine C-C 
motif receptor Monogram Trofile  Monogram Trofile  
Vectibix  EGFR + 
Dakocytomation 
EGFR pharmDx test 
kit 
Dakocytomation 
EGFR pharmDx test 
kit 
  KRAS KRAS LDTs 
DxS TheraScreen 
KRAS 
Iressa EGFR-TK Genzyme EGFR 
DxS TheraScreen 
EGFR 
Ziagen HLA-B *5701 Labcorp HLA B5701 Delphic HLA B5701 
Tarceva EGFR - Genzyme EGFR 
DxS TheraScreen 
EGFR 
Tamoxifen  CYP2D6  variants Roche Amplichip  Roche Amplichip 
Coumadin  
CYP2C9 Variants, 
VKORC1 Variants PGx Predict Warfarin n/a 
Gleevec/Glivec C-Kit 
DakoCytomation C-
Kit PharmDx 
DakoCytomation C-
Kit PharmD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
